Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.7K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
6.1K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.3K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.3K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.2K
3.2K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Retroviruses02:33

Retroviruses

16.1K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
16.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergence in poxvirus-encoded E3-like proteins can dictate poxvirus activation of cellular necroptosis.

Journal of virology·2026
Same author

Poxvirus attack of antiviral defense pathways unleashes an effector-triggered NF-κB response.

Science (New York, N.Y.)·2026
Same author

Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.

Scientific reports·2025
Same author

Effect of Exportin 1/XPO1 Nuclear Export Pathway Inhibition on Coronavirus Replication.

Viruses·2025
Same author

Intergenerational transport of double-stranded RNA in <i>C. elegans</i> can limit heritable epigenetic changes.

eLife·2025
Same author

Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma.

International journal of molecular sciences·2024
Same journal

Dengue Virus Evasion of Host Innate Immunity.

Annual review of virology·2026
Same journal

Geminivirus-Induced Reprogramming of Plant Defense Mechanisms: Molecular Insights and Research Frontiers.

Annual review of virology·2026
Same journal

The Evolution of Dengue Virus in India.

Annual review of virology·2026
Same journal

Studying the Deep Evolution of Viruses in the Era of Artificial Intelligence Structure Prediction.

Annual review of virology·2026
Same journal

Viral Pleomorphism: How Virion Structure Guides Infection and Adaptation.

Annual review of virology·2026
Same journal

Targeting Herpesvirus Recombination Proteins for Antiviral Therapy.

Annual review of virology·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Oncolytic Poxviruses.

Winnie M Chan1, Grant McFadden1

  • 1Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida 32610.

Annual Review of Virology
|April 4, 2015
PubMed
Summary
This summary is machine-generated.

Poxviruses like vaccinia and myxoma are promising candidates for oncolytic virotherapy, selectively destroying cancer cells with a strong safety profile. Combining these oncolytic viruses with traditional treatments may enhance efficacy for incurable cancers.

Keywords:
myxoma virusoncolyticvaccinia virusvirotherapeuticsvirotherapyvirus tropism

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

12.0K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Related Experiment Videos

Last Updated: Apr 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

12.0K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Standard cancer treatments often fail to cure, necessitating novel therapeutic approaches.
  • Oncolytic virotherapy utilizes replication-competent viruses to target and eliminate cancer cells, sparing healthy tissues.
  • Poxviruses, including vaccinia and myxoma, exhibit significant potential as oncolytic agents due to their inherent properties.

Purpose of the Study:

  • To review poxviruses being developed for oncolytic virotherapy.
  • To summarize clinical and preclinical findings of poxvirus-based oncolytic virotherapy.
  • To explore the synergistic effects of combining poxvirus oncolytic virotherapy with conventional cancer treatments.

Main Methods:

  • Review of existing clinical and preclinical studies on poxviruses for oncolytic virotherapy.
  • Analysis of safety and efficacy data from trials involving vaccinia and myxoma viruses.
  • Examination of research on combination therapies involving poxvirus oncolytic virotherapy.

Main Results:

  • Poxviruses demonstrate remarkable safety in clinical and preclinical oncolytic virotherapy studies.
  • Candidate poxviruses show potential for treating various types of currently incurable cancers.
  • Combination of poxvirus oncolytic virotherapy with conventional therapies indicates superior efficacy.

Conclusions:

  • Poxviruses are a viable and safe platform for oncolytic virotherapy.
  • Further development of poxvirus-based therapies holds promise for challenging cancers.
  • Combination strategies may significantly improve treatment outcomes in oncology.